Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 河南羚锐制药股份有限公司是一家以药品、医疗器械生产经营为主业的国家高新技术企业和A股上市公司。公司拥有百余种骨科、心病科、脑病科、麻醉科产品，其中包括通络祛痛膏、壮骨麝香止痛膏、培元通脑胶囊、丹鹿通督片、胃疼宁片、参芪降糖胶囊、芬太尼透皮贴剂等国家中药保护品种和国家医保产品、基药产品。目前，控股、参股多家企业，拥有多个科研、生产基地，其中羚锐制药百亿贴膏剂生产基地领先国内，羚锐信阳健康产业园为国内先进的大型口服药生产基地。公司现有总资产逾40亿元，年创利税近9亿元。公司先后被评为“全国中药工业50强企业”、“全国中药系统先进集体”、“全国精神文明建设工作先进单位”、“国家重点高新技术企业”,公司党委被中组部命名表彰为“全国先进基层党组织”，2018年荣获“中国质量奖提名奖”，2019年，被认定为“国家绿色工厂”，2020年被河南省委、省政府表彰为“河南省抗击新冠肺炎疫情先进集体”，2021年被工信部认定为“国家技术创新示范企业”，2022年入选国家级“智能制造示范工厂”。
Main Business 药品的研发、生产与销售。
Legal Representative 熊伟
Top Executives
董事长：熊伟
董事：陈燕,潘滋润,赵志军,冯国鑫,熊伟,吴希振
独立董事：梅夏英,李慧,杨钧
Top 5 Shareholder
Shareholder name Nature Holding Date
河南羚锐集团有限公司流通A股21.48%31/03/2024
中国工商银行股份有限公司－广发稳健回报混合型证券投资基金流通A股2.30%31/03/2024
信阳新锐投资发展有限公司流通A股1.92%31/03/2024
香港中央结算有限公司流通A股1.76%31/03/2024
中国工商银行－广发稳健增长证券投资基金流通A股1.76%31/03/2024
Company Secretary 冯国鑫
Solicitors 北京市中伦律师事务所
Auditors 大华会计师事务所（特殊普通合伙）
Tel No 0376-2973569
Fax No 0376-2987888
Website www.lingrui.com/
Email 600285@lingrui.com；fengguoxin@lingrui.com；maogaili@lingrui.com
Company Address
Register: 河南省信阳市新县将军路666号
Office: 河南省信阳市新县将军路666号
Listing Date 18/10/2000
Shares Capital
Shares Capital: 567,140,242
Total A Share: 567,140,242
Listed A Share: 563,187,232
Non-tradable A Share: 3,953,010
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.012
DPS(RMB)* ¥ 0.800
NBV Per Share(RMB)* ¥ 4.921
Market Capitalization(RMB) 14.114B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.